首页> 外文期刊>Clinical neurology and neurosurgery >Intracranial atheromatous disease treatment with the Wingspan stent system: Evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results
【24h】

Intracranial atheromatous disease treatment with the Wingspan stent system: Evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results

机译:使用Wingspan支架系统治疗颅内动脉粥样硬化疾病:评估21例连续,单中心的急性和中期结果的临床,手术结局和再狭窄率

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Intracranial atherosclerosis may be the underlying pathology in up to 15% of ischemic strokes, but may account for about 40% of strokes in some populations. After an ischemic event determined by intracranial atherosclerosis, patients have a 12% annual risk of stroke recurrence, mostly during the first year. Objective: To evaluate procedural safety, clinical outcome and restenosis rate of Wingspan stent placement. Methods: Twenty-one caucasoid patients were enrolled. Target patients were affected by high-grade, symptomatic, intracranial atherosclerotic lesions, were on antithrombotic therapy and at high stroke risk. All patients were treated with the Wingspan stent system. Results: Technical success resulted 100%, with all target lesions being reduced to < 50%. No stroke or death were observed at 30. The mean percent of stenosis was reduced from a middle value of 84% to a middle value of 17% after stent placement. Medium follow-up was 19.5 months (range 6-36 months). No stroke or death occurred in any patient. None of the patients presented a <50% stent patency rate at follow-up. Conclusions: The short-term results and follow up analysis provide evidence demonstrating the safety of the Wingspan system when used in high-risk patient population. Due to concerns regarding long-term stent patency and ischemic events occurrence emerged from clinical trials such as the SAMMPRIS, intracranial angioplasty and stent with the Wingspan system should be considered only for high risk patients in which it may be considered the only viable therapeutic option.
机译:背景:颅内动脉粥样硬化可能是多达15%的缺血性中风的潜在病理,但在某些人群中可能占约40%的中风。由颅内动脉粥样硬化确定的局部缺血事件后,患者每年发生中风复发的风险为12%,大部分发生在第一年。目的:评价Wingspan支架置入的过程安全性,临床结局和再狭窄率。方法:二十一高加索患者入组。目标患者受到高级别,有症状的颅内动脉粥样硬化病变的影响,正在接受抗栓治疗,并有中风的高风险。所有患者均接受Wingspan支架系统治疗。结果:技术成功率达100%,所有目标病变均降至<50%。 30岁时未观察到卒中或死亡。置入支架后,狭窄的平均百分比从84%的中间值降低到17%的中间值。中度随访为19.5个月(6-36个月)。任何患者均未发生中风或死亡。随访时无患者支架通畅率<50%。结论:短期结果和后续分析提供了证据,证明了Wingspan系统在高风险患者人群中使用时的安全性。由于担心长期支架通畅和缺血事件的发生,例如SAMMPRIS,颅内血管成形术和带有Wingspan系统的支架等临床试验中出现的情况,仅对于可能被认为是唯一可行治疗选择的高风险患者应予以考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号